The new box is now called Box 2.0. The new design is a consistent, modern further development of the original product outfit.

At the beginning of September, Stephan Goldenbaum became the new CEO of Estonian Solis BioDyne OÜ. CEO Priit Karjus stepped down to continue the Supervisory Board.

EnteroBiotix closes an oversubscribed Series A financing with US$21.5m. The biopharma company will use the proceeds to advance its microbiome drug pipeline.

The Swiss biopharmaceutical industry is on the verge of record growth: This was demonstrated at the live Swiss Biotech Day in Basel.

Owlstone Medical has raised US$59m in a Series D financing round. The proceeds will be used to continue development of the company’s breath biopsy tests.

Timo van den Berg is the new senior director Immuno-Oncology Research and Development at Byondis B.V. He joined the company at beginning

The EU Commission and AstraZeneca have settled their ongoing legal dispute over the supply of COVID-19 vaccine doses. They agreed to a new delivery schedule.

EuropaBio has responded to the European Commission’s public consultation on the Orphan Medicinal Products (OMPs) and Paediatrics Regulations.

Swiss rare disease specialist VectivBio Holding AG is taking over US biotech Comet Therapeutics Inc. for an undisclosed amount. Comet focusses on treatments for metabolic diseases.

With new backing from large pharma, rising investors interest, and new incubators on stage, the AMR community is now urging policy makers worldwide to bring pull incentives into reality.